For the Inventor, By the Inventor

Enter assignee name

Oss, Netherlands

Synaffix B.v.

USPTO Granted Patents = 30

EPO Patents = 18

Trademarks = 6

Forward Citations = 321

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Floris Louis Van Delft (30 out of 31 patents)

Maria Antonia Wijdeven (21 out of 21 patents)

Sander Sebastiaan Van Berkel (17 out of 17 patents)

4. Remon Van Geel (14 out of 14 patents)

5. Jorge Merijn Mathieu Verkade (11 out of 12 patents)

6. Frederik Jan Dommerholt (7 out of 7 patents)

7. Petrus Josephus Jacobus Maria Van De Sande (7 out of 7 patents)

8. Ryan Heesbeen (6 out of 6 patents)

9. Floris Petrus Johannes Theodorus Rutjes (5 out of 6 patents)

10. Inge Catharina Josephina Hurkmans (4 out of 4 patents)

11. Brian Maria Gerardus Janssen (2 out of 2 patents)

12. Jorin Hoogenboom (2 out of 3 patents)

13. Anna Agnieszka Wasiel (1 out of 1 patent)

14. Remon Gvan Eel (1 out of 1 patent)

15. Lianne Lelieveldt (1 out of 1 patent)

30 patents: Sort by Forward Citations

1. 12440573 - Antibody-conjugates for targeting of tumours expressing PTK7 (2025-10-14),

2. 12397063 - Antibody-conjugates for targeting of tumours expressing Trop-2 (2025-08-26),

3. 12281135 - Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate (2025-04-21),

4. 12194107 - Modified antibody, antibody-conjugate and process for the preparation thereof (2025-01-14),

5. 12180145 - Fused cyclooctyne compounds and their use in metal-free click reactions (2024-12-31),

6. 12084448 - Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne (2024-09-10),

7. 12049656 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2024-07-30),

8. 11957763 - Sulfamide linkers for use in bioconjugates (2024-04-16),

9. 11951175 - Bioconjugates containing sulfamide linkers for use in treatment (2024-04-09),

10. 11850286 - Sulfamide linker, conjugates thereof, and methods of preparation (2023-12-26),

11. 11713453 - Enzymes for trimming of glycoproteins (2023-08-01),

12. 11590239 - Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates (2023-02-28),

13. 11358921 - Fused cyclooctyne compounds and their use in metal-free click reactions (2022-06-14),

14. 11338043 - Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates (2022-05-24),

15. 11299759 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2022-04-12),

SYNAFFIX B.V. is a biotechnology company that specializes in the development of proprietary technologies and solutions for antibody-drug conjugate (ADC) development and optimization. Their advanced technology platform enables the creation of site-specific and homogeneous ADCs, enhancing the therapeutic potential of these targeted cancer therapies. With a focus on innovation and collaboration, SYNAFFIX aims to improve patient outcomes through the advancement of ADC technology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

30 Patents

#2 in Oss

#245 in Netherlands

#21,181 in the World

Oss, Netherlands

Synaffix B.v.

Forward Citations = 321

20 inventors:

Floris Louis Van Delft (30 out of 31 patents)

Maria Antonia Wijdeven (21 out of 21 patents)

Sander Sebastiaan Van Berkel (17 out of 17 patents)

4. Remon Van Geel (14 out of 14 patents)

5. Jorge Merijn Mathieu Verkade (11 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…